239 related articles for article (PubMed ID: 19164803)
1. The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.
Boyanovsky B; Zack M; Forrest K; Webb NR
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):532-8. PubMed ID: 19164803
[TBL] [Abstract][Full Text] [Related]
2. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans.
Boyanovsky BB; van der Westhuyzen DR; Webb NR
J Biol Chem; 2005 Sep; 280(38):32746-52. PubMed ID: 16040605
[TBL] [Abstract][Full Text] [Related]
3. Group V secretory phospholipase A2 enhances the progression of angiotensin II-induced abdominal aortic aneurysms but confers protection against angiotensin II-induced cardiac fibrosis in apoE-deficient mice.
Boyanovsky BB; Bailey W; Dixon L; Shridas P; Webb NR
Am J Pathol; 2012 Sep; 181(3):1088-98. PubMed ID: 22813854
[TBL] [Abstract][Full Text] [Related]
4. Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice.
Bostrom MA; Boyanovsky BB; Jordan CT; Wadsworth MP; Taatjes DJ; de Beer FC; Webb NR
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):600-6. PubMed ID: 17204667
[TBL] [Abstract][Full Text] [Related]
5. Phospholipase A(2)-modified LDL particles retain the generated hydrolytic products and are more atherogenic at acidic pH.
Lähdesmäki K; Plihtari R; Soininen P; Hurt-Camejo E; Ala-Korpela M; Oörni K; Kovanen PT
Atherosclerosis; 2009 Dec; 207(2):352-9. PubMed ID: 19473659
[TBL] [Abstract][Full Text] [Related]
6. Hawthorn leaf flavonoids alleviate the deterioration of atherosclerosis by inhibiting SCAP-SREBP2-LDLR pathway through sPLA2-ⅡA signaling in macrophages in mice.
Bai X; Wang S; Shu L; Cao Q; Hu H; Zhu Y; Chen C
J Ethnopharmacol; 2024 Jun; 327():118006. PubMed ID: 38442806
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic arginase 1 deficiency results in decreased leukocytosis and increased foam cell formation but does not affect atherosclerosis.
Ren B; Van Kampen E; Van Berkel TJ; Cruickshank SM; Van Eck M
Atherosclerosis; 2017 Jan; 256():35-46. PubMed ID: 27998825
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL.
Boyanovsky BB; Shridas P; Simons M; van der Westhuyzen DR; Webb NR
J Lipid Res; 2009 Apr; 50(4):641-50. PubMed ID: 19056705
[TBL] [Abstract][Full Text] [Related]
9. Myeloid Kdm6b deficiency results in advanced atherosclerosis.
Neele AE; Gijbels MJJ; van der Velden S; Hoeksema MA; Boshuizen MCS; Prange KHM; Chen HJ; Van den Bossche J; van Roomen CPPA; Shami A; Levels JHM; Kroon J; Lucas T; Dimmeler S; Lutgens E; de Winther MPJ
Atherosclerosis; 2018 Aug; 275():156-165. PubMed ID: 29908485
[TBL] [Abstract][Full Text] [Related]
10. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.
Sato H; Kato R; Isogai Y; Saka G; Ohtsuki M; Taketomi Y; Yamamoto K; Tsutsumi K; Yamada J; Masuda S; Ishikawa Y; Ishii T; Kobayashi T; Ikeda K; Taguchi R; Hatakeyama S; Hara S; Kudo I; Itabe H; Murakami M
J Biol Chem; 2008 Nov; 283(48):33483-97. PubMed ID: 18801741
[TBL] [Abstract][Full Text] [Related]
11. Low carbohydrate, high protein diet promotes atherosclerosis in apolipoprotein E/low-density lipoprotein receptor double knockout mice (apoE/LDLR(-/-)).
Kostogrys RB; Franczyk-Żarów M; Maślak E; Gajda M; Mateuszuk L; Jackson CL; Chłopicki S
Atherosclerosis; 2012 Aug; 223(2):327-31. PubMed ID: 22771189
[TBL] [Abstract][Full Text] [Related]
12. Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines.
Boyanovsky BB; Li X; Shridas P; Sunkara M; Morris AJ; Webb NR
Cytokine; 2010 Apr; 50(1):50-7. PubMed ID: 20138782
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of Atherogenic Effects of Low Carbohydrate, High Protein Diet (LCHP) in ApoE/LDLR-/- Mice.
Kostogrys RB; Johann C; Czyżyńska I; Franczyk-Żarów M; Drahun A; Maślak E; Jasztal A; Gajda M; Mateuszuk Ł; Wrobel TP; Baranska M; Wybrańska I; Jezkova K; Nachtigal P; Chlopicki S
J Nutr Health Aging; 2015 Aug; 19(7):710-8. PubMed ID: 26193853
[TBL] [Abstract][Full Text] [Related]
14. Effect of macrophage-derived apolipoprotein E on hyperlipidemia and atherosclerosis of LDLR-deficient mice.
Shi W; Wang X; Wong J; Hedrick CC; Wong H; Castellani LW; Lusis AJ
Biochem Biophys Res Commun; 2004 Apr; 317(1):223-9. PubMed ID: 15047172
[TBL] [Abstract][Full Text] [Related]
15. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
16. ApoE-dependent modulation of HDL and atherosclerosis by G2A in LDL receptor-deficient mice independent of bone marrow-derived cells.
Parks BW; Srivastava R; Yu S; Kabarowski JH
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):539-47. PubMed ID: 19164809
[TBL] [Abstract][Full Text] [Related]
17. Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis.
Patel KM; Strong A; Tohyama J; Jin X; Morales CR; Billheimer J; Millar J; Kruth H; Rader DJ
Circ Res; 2015 Feb; 116(5):789-96. PubMed ID: 25593281
[TBL] [Abstract][Full Text] [Related]
18. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.
Hanasaki K; Yamada K; Yamamoto S; Ishimoto Y; Saiga A; Ono T; Ikeda M; Notoya M; Kamitani S; Arita H
J Biol Chem; 2002 Aug; 277(32):29116-24. PubMed ID: 12021277
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase.
Sukhanov S; Snarski P; Vaughn C; Lobelle-Rich P; Kim C; Higashi Y; Shai SY; Delafontaine P
Atherosclerosis; 2015 Feb; 238(2):313-20. PubMed ID: 25549319
[TBL] [Abstract][Full Text] [Related]
20. Anti-atherosclerotic effects of pravastatin in brachiocephalic artery in comparison with en face aorta and aortic roots in ApoE/LDLR
Kostogrys RB; Franczyk-Zarow M; Gasior-Glogowska M; Kus E; Jasztal A; Wrobel TP; Baranska M; Czyzynska-Cichon I; Drahun A; Manterys A; Chlopicki S
Pharmacol Rep; 2017 Feb; 69(1):112-118. PubMed ID: 27915184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
